Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Myelosuppression × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2467 Carcinoma, Non-Small-Cell Lung 2005 Prostatic Neoplasms 1298 Colorectal Neoplasms 1148 Neoplasms 1101 Multiple Myeloma 956 Lung Neoplasms 939 Neoplasm Metastasis 890 Leukemia, Myeloid, Acute 865 Lymphoma 800 Melanoma 776 Pancreatic Neoplasms 733 Ovarian Neoplasms 719 Carcinoma, Hepatocellular 691 Stomach Neoplasms 678 Recurrence 675 Leukemia 656 Lymphoma, Non-Hodgkin 611 Leukemia, Lymphocytic, Chronic, B-Cell 587 Squamous Cell Carcinoma of Head and Neck 548 Lymphoma, Large B-Cell, Diffuse 547 Brain Neoplasms 537 Head and Neck Neoplasms 532 Precursor Cell Lymphoblastic Leukemia-Lymphoma 530 Glioblastoma 519 Carcinoma, Renal Cell 513 Rectal Neoplasms 501 Myelodysplastic Syndromes 465 Sarcoma 463 Lymphoma, Follicular 456

Interventions

trilaciclib 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡